Home > Site map > Report overview

Botulinum Toxin

Published by: Global Industry Analysts

Published: Oct. 1, 2011 - 187 Pages

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS: Study Reliability and Reporting Limitations; Disclaimers; Data Interpretation & Reporting Level; Product Definitions and Scope of Study
2. INDUSTRY OVERVIEW: A Prelude; Current and Future Scenario; Botulinum Toxin: “The Science, The Hopes & the Risks”; Future Opportunities Span Beyond The Developed Markets
3. TRENDS & ISSUES: Acceptance for Cosmetic BTX Treatment Grows; Aging Population: A Weighty Demographic Driver; Unmet Medical Needs Encourage Off-Label Use: A Cause for Concern or Jubilation?; High Voltage Ad Campaigns Boost Patient Awareness; Societal Pressure to Look Young Drives up Demand for Facial Aesthetics; Cosmetic Botulinum Toxin to Feel the Pinch of the Recession; Financing of Non-Reimbursed Healthcare: The Need of the Hour; Combination Therapies: A Double Whammy Success; Short Lived Aesthetic Effects: A Strong Business Case for Revision Treatments; Consolidation Blows in the Aesthetic Healthcare Industry; Undesirable Side Effects: A Challenge to Reckon With; Immunogenicity Undermines Patient Compliance; Antigenicity: One of the Most Problematic Issues in Drug Development; Stringent Regulations Delay Market Approval & Put Reimbursements in Limbo; Non-Injectable Alternatives to Turn On the Heat; Fears of Terrorism & Biological Warfare Thwart International Trade; Competition; Market Share Statistics
4. PRODUCT OVERVIEW: Botulinum Toxin: A Poison That Cures; Classification of Botulinum Toxin; Applications of Botulinum Toxin; Therapeutic Applications
5. PRODUCT APPROVALS & INTRODUCTIONS: SMC Approves the Use of Botox® for the Treatment of Focal Spasticity; Merz Launches Xeomin in the US; Ipsen Launches Dysport in US; Ipsen and Medicis Receives FDA Approval for DysportTM; Xeomin Receives Approval From European Health Authorities; Ranbaxy and MedyTox Collaborates to Launch Neuronox; GlaxoSmithKline Receives Approval for Botox Vista; Galderma and Ipsen Obtain Marketing Authorization for Azzalure; Azzalure® Gains Approval from 15 European Countries; Inclusion of New Side Effect in Botox and Botox Cosmetic Labels; Azzalure® Gains Approval for Aesthetic Application in the UK; Ipsen and Medicis File BLA for Reloxin®; Allergan and Clinique Launch New Skin Care Products; FDA Accepts Ipsen's Filing for Reloxin; GlaxoSmithKline Gains Approval for BOTOX® in Japan; Mentor Completes Phase IIIb Trial for Its Botulinum Toxin Type A Product; Allergan Commences Botox Study for Urological Cases in India; FDA Accepts BLA Filing for Dysport® in Cervical Dystonia Cases; Allergan Successfully Completes Analysis of Two Phase III Trials for BOTOX®; Allergan to Launch New Products in India
6. RECENT INDUSTRY ACTIVITY: US WorldMeds Takes Over Solstice Neurosciences; Johnson & Johnson Acquires Mentor Corporation; Ranbaxy Signs an in-Licensing Agreeement with Medy-Tox; Ranbaxy Signs Marketing Agreement with MedyTox; Revance and Medicis Sign Licensing Agreement; GlaxoSmithKline and Wakamoto Pharmaceutical Collaborate to Market Botox; BioForm Medical Acquires Advanced Cosmetic Intervention; Galderma to Acquire CollaGenex; Allergan and Clinique Form Strategic Collaboration; Allergan to Set Up a New Subsidiary in India; Allergan Join Hands with India-Based Kaya; Q-Med and Medy-Tox Cancel the Collaboration Agreement; Galderma to Increase Awareness in Brazil; Galderma Receives License to Market Dysport
7. FOCUS ON SELECT KEY PLAYERS: Allergan, Inc (US); Ipsen Group (France); Lanzhou Institute of Biological Products (China); Metabiologics Inc, (US); Merz Pharmaceuticals GmbH (Germany); Mentor Corporation (US); Medy-Tox Incorporated (South Korea); Medicis Pharmaceutical Corporation (US); Solstice Neurosciences, Inc. (US)
8. GLOBAL MARKET PERSPECTIVE: Table 13: World Recent Past, Current & Future Analysisfor Botulinum Toxin by Geographic Region/Country -US, Europe and Rest of World Markets IndependentlyAnalyzed by Annual Sales in US$ Millionfor the Years 2009 through 2017 (includescorresponding Graph/Chart); Table 14: World Historic Review for Botulinum Toxin byGeographic Region/Country - US, Europe and Rest of WorldMarkets Independently Analyzed by Annual Salesin US$ Million For the Years 2003 through 2008(includes corresponding Graph/Chart); Table 15: World 15-Year Perspective for Botulinum Toxin by Geographic Region - Percentage Breakdownof Dollar Sales for US, Europe and Rest of World Marketsfor the Years 2003, 2010 & 2017 (includescorresponding Graph/Chart); Table 16: World Recent Past, Current & Future Analysisfor Botulinum Toxin in Cosmetic Applications by GeographicRegion - US, Europe and Rest of World Markets Independently Analyzed by Annual Sales in US$ Million for the Years 2009through 2017 (includes corresponding Graph/Chart); Table 17: World Historic Review for Botulinum Toxin in Cosmetic Applications by Geographic Region - US, Europeand Rest of World Markets Independently Analyzed byAnnual Sales in US$ Million for the Years 2003 through2008 (includes corresponding Graph/Chart); Table 18: World 15-Year Perspective for Botulinum Toxinin Cosmetic Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for the Years 2003, 2010 &2017 (includes corresponding Graph/Chart); Table 19: World Recent Past, Current & Future Analysisfor Botulinum Toxin in Therapeutic Applications byGeographic Region - US, Europe and Rest of WorldMarkets Independently Analyzed by Annual Salesin US$ Million for the Years 2009 through 2017(includes corresponding Graph/Chart); Table 20: World Historic Review for Botulinum Toxinin Therapeutic Applications by Geographic Region - US,Europe and Rest of World Markets Independently Analyzedby Annual Sales in US$ Million for the Years 2003 through2008 (includes corresponding Graph/Chart); Table 21: World 15-Year Perspective for Botulinum Toxin in Therapeutic Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for the Years 2003, 2010 &2017 (includes corresponding Graph/Chart); Table 22: World Recent Past, Current & Future Analysisfor Botulinum Toxin in Therapeutic Application by Disease Indication - Movement Disorders/Pain, Headache,Hyperhidrosis, Overactive Bladder and Spasticity-Markets Analyzed with Annual Sales Figuresin US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart); Table 23: Global Historic Review for Botulinum Toxin in Therapeutic Application by Disease Indication -Movement Disorders/Pain, Headache, Hyperhidrosis,Overactive Bladder and Spasticity- MarketsAnalyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includescorresponding Graph/Chart); Table 24: World 15-Year Perspective for Botulinum Toxin in Therapeutic Application by Disease Indication - Percentage Breakdown of Dollar Salesfor Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder and Spasticity - Marketsfor the Years 2003, 2010 & 2017 (includescorresponding Graph/Chart)
9. THE UNITED STATES: A. Market Analysis; B. Market Analytics
10. EUROPE: A. Market Analysis; B. Market Analytics
11. REST OF WORLD: A. Market Analysis; B. Market Analytics
COMPETITIVE LANDSCAPE: Total Companies Profiled: 19 (including Divisions/Subsidiaries - 22)Region/Country Players; The United States; Japan 2; Europe; Asia-Pacific (Excluding Japan)

Abstract

This report analyzes the worldwide markets for Botulinum Toxin in US$ Million by the following Product Segments: Cosmetic Applications, and Therapeutic Applications (Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder, & Spasticity). The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets.The report profiles 19 companies including many key and niche players such as Allergan, Inc., Ipsen Group, Lanzhou Institute of Biological Products, Metabiologics, Inc., Merz Pharmaceuticals GmbH, Mentor Corporation, Medy-Tox Incorporated, Medicis Pharmaceutical Corporation, and Solstice Neurosciences, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

Get full details about this report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Botulinum Toxin

Table of Contents

Abstract

US: 800.298.5699

Int'l: +1.240.747.3093